stephen wiviott, md: strengths and limitations of the declare-timi 58 trial
Published 5 years ago • 783 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
3:09
stephen wiviott, md: declare-timi 58 trial
-
7:05
aha 2018: declare timi-58- prof stephen d. wiviott
-
5:38
declare-timi 58 with dr. stephen wiviott
-
6:26
ofri mosenzon, md: declare-timi 58 results
-
5:10
results declare-timi 58
-
3:32
sglt-2 in cardiovascular and kidney outcomes declare timi 58
-
2:47
diabetes and cardiovascular health: what you need to know
-
6:57
how does dapagliflozin work? understanding sglt2 inhibitors.
-
11:19
ehj today - the empa-reg outcome trial
-
2:12
stephen wiviott, md: changes in the treatment of type 2 diabetes
-
34:54
professor stephen wiviott - 'sglt2 outcome trials - an evolving story'
-
1:37
stephen wiviott, md: acc/aha recommendations for sglt-2 use
-
9:46
stephen wiviott, md
-
9:37
cardiovascular outcomes trials with anti-diabetes medications
-
2:58
steven zelenkofske, do, describes the success of sglt-2 inhibitors in the cvd-real study
-
5:12
understanding cardiovascular outcomes trials
-
1:51
esc 2016: treatment of patients with stemi and multivessel disease
-
1:45
new device could mean end of the jab for people living with diabetes
-
1:34
heart minute | extra effects of bivalirudin in stemi
-
13:58
e-26: cvdi cardiovascular risk calculator
-
2:36
how can we get diagnostics to patients faster?
-
2:07
dr. steven hsu | cardiology